Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling

Richard M. Van Rijn, Jessica H. Harvey, Daniela I. Brissett, Julia N. DeFriel, Jennifer Whistler

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to form heteromers with unique signaling properties suggests an entirely new and unexplored pool of drug targets. However, current in vitro assays are ill equipped to detect heteromer-selective compounds. We have successfully adapted an approach, using fusion proteins of GPCRs and chimeric G proteins, to create an in vitro screening assay (in human embryonic kidney cells) in which only activated heteromers are detectable. Here we show that this assay can demonstrate heteromer-selective G-protein bias as well as measure transinhibition. Using this assay, we reveal that the δ-opioid receptor agonist ADL5859, which is currently in clinical trials, has a 10-fold higher potency against δ-opioid receptor homomers than δ/μ-opioid receptor heteromers (pEC50 = 6.7 ± 0.1 versus 5.8 ± 0.2). The assay enables the screening of large compound libraries to identify heteromer-selective compounds that could then be used in vivo to determine the functional role of heteromers and develop potential therapeutic agents.

Original languageEnglish (US)
Pages (from-to)179-188
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume344
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Opioid Receptors
G-Protein-Coupled Receptors
GTP-Binding Proteins
Drug Delivery Systems
Libraries
Clinical Trials
Kidney
Pharmaceutical Preparations
Proteins
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling. / Van Rijn, Richard M.; Harvey, Jessica H.; Brissett, Daniela I.; DeFriel, Julia N.; Whistler, Jennifer.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 344, No. 1, 01.01.2013, p. 179-188.

Research output: Contribution to journalArticle

Van Rijn, Richard M. ; Harvey, Jessica H. ; Brissett, Daniela I. ; DeFriel, Julia N. ; Whistler, Jennifer. / Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling. In: Journal of Pharmacology and Experimental Therapeutics. 2013 ; Vol. 344, No. 1. pp. 179-188.
@article{e430aa33ae4248cdb606bf1e4366ffa3,
title = "Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling",
abstract = "Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25{\%} of all prescribed medicines. The ability of GPCRs to form heteromers with unique signaling properties suggests an entirely new and unexplored pool of drug targets. However, current in vitro assays are ill equipped to detect heteromer-selective compounds. We have successfully adapted an approach, using fusion proteins of GPCRs and chimeric G proteins, to create an in vitro screening assay (in human embryonic kidney cells) in which only activated heteromers are detectable. Here we show that this assay can demonstrate heteromer-selective G-protein bias as well as measure transinhibition. Using this assay, we reveal that the δ-opioid receptor agonist ADL5859, which is currently in clinical trials, has a 10-fold higher potency against δ-opioid receptor homomers than δ/μ-opioid receptor heteromers (pEC50 = 6.7 ± 0.1 versus 5.8 ± 0.2). The assay enables the screening of large compound libraries to identify heteromer-selective compounds that could then be used in vivo to determine the functional role of heteromers and develop potential therapeutic agents.",
author = "{Van Rijn}, {Richard M.} and Harvey, {Jessica H.} and Brissett, {Daniela I.} and DeFriel, {Julia N.} and Jennifer Whistler",
year = "2013",
month = "1",
day = "1",
doi = "10.1124/jpet.112.198655",
language = "English (US)",
volume = "344",
pages = "179--188",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling

AU - Van Rijn, Richard M.

AU - Harvey, Jessica H.

AU - Brissett, Daniela I.

AU - DeFriel, Julia N.

AU - Whistler, Jennifer

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to form heteromers with unique signaling properties suggests an entirely new and unexplored pool of drug targets. However, current in vitro assays are ill equipped to detect heteromer-selective compounds. We have successfully adapted an approach, using fusion proteins of GPCRs and chimeric G proteins, to create an in vitro screening assay (in human embryonic kidney cells) in which only activated heteromers are detectable. Here we show that this assay can demonstrate heteromer-selective G-protein bias as well as measure transinhibition. Using this assay, we reveal that the δ-opioid receptor agonist ADL5859, which is currently in clinical trials, has a 10-fold higher potency against δ-opioid receptor homomers than δ/μ-opioid receptor heteromers (pEC50 = 6.7 ± 0.1 versus 5.8 ± 0.2). The assay enables the screening of large compound libraries to identify heteromer-selective compounds that could then be used in vivo to determine the functional role of heteromers and develop potential therapeutic agents.

AB - Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to form heteromers with unique signaling properties suggests an entirely new and unexplored pool of drug targets. However, current in vitro assays are ill equipped to detect heteromer-selective compounds. We have successfully adapted an approach, using fusion proteins of GPCRs and chimeric G proteins, to create an in vitro screening assay (in human embryonic kidney cells) in which only activated heteromers are detectable. Here we show that this assay can demonstrate heteromer-selective G-protein bias as well as measure transinhibition. Using this assay, we reveal that the δ-opioid receptor agonist ADL5859, which is currently in clinical trials, has a 10-fold higher potency against δ-opioid receptor homomers than δ/μ-opioid receptor heteromers (pEC50 = 6.7 ± 0.1 versus 5.8 ± 0.2). The assay enables the screening of large compound libraries to identify heteromer-selective compounds that could then be used in vivo to determine the functional role of heteromers and develop potential therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=84871686505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871686505&partnerID=8YFLogxK

U2 - 10.1124/jpet.112.198655

DO - 10.1124/jpet.112.198655

M3 - Article

C2 - 23097213

AN - SCOPUS:84871686505

VL - 344

SP - 179

EP - 188

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -